Vaginal Progesterone effect on pregnancy rate in infertility women with polycystic ovarian syndrome

Evaluation of efficacy of vaginal progesterone on pregnancy rate in women with polycystic ovarian syndrome using combination therapies for ovulation induction

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201206072967N4

Enrollment

200

Registered

2012-10-07

Start date

2012-07-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility and Polycystic Ovarian Syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group 1: letrozole (Femara

Novartis Pharma AG, Switzerland) 5 mg daily during 3-7 days of menstruation and then, 150 IU gonadotropin (Merional, IBSA, Switzerland) daily will be given from 5-9 days of cycle. After day 10 of the

Treatment - Drugs

Control group 2: clomiphene (100 mg, daily) during 3-7 days of menstruation and then, 150 IU gonadotropin (Merional, IBSA, Switzerland) daily will be given from 5-9 days of cycle. After day 10 of the

Intervention group 1: letrozole (Femara

Intervention group 2: clomiphene (100 mg, daily) during 3-7 days of menstruation and then, 150 IU gonadotropin (Merional, IBSA, Switzerland) daily will be given from 5-9 days of cycle. After day 10 of

Control group 1: letrozole (Femara

Eligibility

Sex/Gender

Female

Age

20 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria consist 20 -35 years, having Rotterdam criteria (having 2 from 3 following criteria: Oligomenorrehea or amenorrhea, polycystic ovaries in sonography, clinical or biochemical evidences of hyperandrogenism). The patient with abnormal hormonal assay in the third day of menstruation (including FSH, TSH, prolactin, 17 Hydroxy progesterone and testosterone), tubal obstruction in HSG or laparoscopy and infertility due to male factor will be excluded.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pregnancy. Timepoint: Last day of receiving progesterone suppository. Method of measurement: Blood test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Fatemeh Foroozanfard

Kashan University of Medical Sciences

fatemehforoozanfard@yahoo.com? forozanfar_f@kaums.ac.ir+98 36 1542 1355

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026